INCYTE CORP (INCY)
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
📈 **POSITIVE** • High confidence analysis (80%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business